PROTEMBIS
26.3.2024 07:01:30 CET | Business Wire | Press release
Protembis GmbH (Protembis), a privately-held emerging cardiovascular medical device company, announced today the completion of a € 30 million Series B financing round to support the enrollment of the PROTEMBO Investigational Device Exemption (IDE) Pivotal Trial (NCT05873816). The funding round was structured in two separate capital increases which have both been completed. It was co-led by a European consortium of VC investors including Sweden-based Segulah Medical Acceleration, Italy-based XGEN Venture, and Germany-based TechVision Fund. Other investors include Coparion, several large family offices, angel investors and a multinational medical device strategic.
“We are delighted to announce the completion of the round and would like to thank our existing investors as well as the new investors for their trust and confidence,” said Karl von Mangoldt and Conrad Rasmus Co-CEOs of Protembis. “It reflects the fact that the field of cerebral embolic protection is buoyant, and that future growth will be driven by younger and lower risk patients who have zero tolerance for brain injury risk when selecting to undergo transcatheter aortic valve replacement.”
Additionally, Protembis is proud to announce the addition of Keith D. Dawkins, MD, to the Board of Directors. Dr Dawkins has more than 35 years’ experience in the cardiovascular environment. With over 20 years as a practicing interventional cardiologist in the UK he has held research roles as a Fulbright Scholar at Stanford University, served as President of the British Cardiovascular Intervention Society, and authored more than 750 academic publications and presentations. Dr Dawkins has been the Chief Medical Officer (CMO) of Shockwave (NASDAQ:SWAV) since 2019, and this was preceded by his role as Global CMO at Boston Scientific where he held senior positions since 2008. He also serves as a member of the boards of Ventric Health LLC and JenaValve Technology Inc., as well as Chairman of InnovHeart s.r.l. Dr Dawkins will contribute his significant expertise to the clinical strategies of Protembis and the pre-commercial programs as the IDE study reaches its conclusion.
“To have such a visionary leader as Dr Dawkins join our Board of Directors is an exciting indication of the opportunities that cerebral embolic protection holds for future transcatheter therapies. We look forward to close collaboration as the field develops and our superiority trial gains momentum,” said Azin Parhizgar, PhD, Chairwoman of the Board of Directors.
“As a long-term believer in the need to protect the brain from all new lesions during transcatheter aortic valve replacement, I am very pleased to join Protembis,” said Dr Dawkins. “The ProtEmbo System and the clinical trial design are both novel and I am confident that they will be highly disruptive to the field of cerebral embolic protection, removing or mitigating many of the current issues that concern the physician community.”
About ProtEmbo® and Protembis
The ProtEmbo® Cerebral Protection System is an intra-aortic filter device that protects the entire brain from embolic material liberated during transcatheter aortic valve replacement (TAVR). It is a low-profile non thrombogenic system that shields all cerebral vessels, delivered through the left radial artery for optimal placement and stability. This is an ideal access site enabling physicians to avoid interference with TAVR equipment typically delivered through the femoral artery.
Protembis is a privately held emerging medical device company that has developed the ProtEmbo® Cerebral Protection System. The company strives to provide a simple and reliable solution to protect patients from brain injury during left-sided heart procedures, improving patient quality of life and reducing overall healthcare costs associated with brain injury during such procedures. The ProtEmbo System is currently undergoing clinical investigations.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240325053798/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rezon Bio Appoints Dr. Hubert Scholze as Chief Business Officer to Accelerate Global Commercial Expansion1.7.2026 12:01:00 CEST | Press release
Rezon Bio, a science-driven European biologics contract development and manufacturing organization (CDMO), today announced the appointment of Dr. Hubert Scholze as Chief Business Officer (CBO), effective July 1, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260701630118/en/ Dr. Hubert Scholze, Chief Business Officer, Rezon Bio As a member of Rezon Bio’s Executive Leadership Team, Dr. Hubert Scholze will lead the company’s commercial functions, overseeing Business Development, Market Intelligence, Global Marketing, Proposal Management and Project Management. Hubert Scholze, PhD will be responsible for Rezon Bio’s commercial strategy, strengthening strategic partnerships, supporting the company’s continued international growth, and ensuring a seamless client experience from initial engagement to program execution. His appointment comes at pivotal moment for Rezon Bio as the company continues to strengthen its integrated
CoStar Group Invests in Wikicasa, Italy’s Agent-Backed Real Estate Marketplace1.7.2026 12:00:00 CEST | Press release
Transaction will result in an approximately 30% stake in the company and support innovation and digital transformation in the Italian real estate market CoStar Group, Inc. (NASDAQ: CSGP), a global leader in online real estate marketplaces, information, analytics and 3D digital twin technology in the property markets, today announced an investment in Wikicasa, Italy’s agent-backed real estate marketplace. The transaction will result in CoStar Group acquiring an approximately 30% stake in Wikicasa. Wikicasa’s shareholder base includes Italy’s leading real estate agencies - including Tecnocasa Group, Gabetti Group, RE/MAX Italy, and Tempocasa. Wikicasa.it is an agent-driven platform that brings together leading real estate professionals across Italy to deliver a high-quality, data-rich marketplace of over 600,000 listings, more than 100,000 of which are commercial. It provides consumers with comprehensive property listings while equipping agents with modern data and intelligence tools to
Forrester Announces The Conference Agenda For B2B Forum EMEA 20261.7.2026 11:46:00 CEST | Press release
The event will help B2B leaders modernise their go-to-market strategies to navigate AI-enabled buyer autonomy Forrester (Nasdaq: FORR) today announced the full conference agenda for its B2B Forum EMEA 2026, taking place 28–29 September 2026 in London. Centered on the theme, “Hello, GTM Singularity,” the event will bring together marketing, sales, product, customer success, and revenue leaders to address the collapse of traditional go-to-market (GTM) models. According to Forrester, approximately nine in 10 business buyers now use genAI or conversational search in the buying process. As AI-led discovery, changing buying behaviours, and increasingly complex buying networks continue to disrupt how customers discover, evaluate, and purchase solutions, organisations must integrate their GTM approach as a unified system that builds visibility, preference, and trust. Designed as an intimate event for senior B2B leaders, B2B Forum EMEA 2026 will combine keynote presentations, analyst-led sessio
Ant International Unveils Global Development Centre in Malaysia, Expanding Commitment to AI, Talent, Trust and Digital Innovation1.7.2026 11:06:00 CEST | Press release
Ant International is developing around 1,500 talents in Kuala Lumpur, with more than half in tech-related roles, supporting the company’s global innovations and business growthSpending by Alipay+ partners via the DuitNow national QR increased more than 60%, driving travel-led economic impact as the country celebrates Visit Malaysia 2026Since launching in January 2026 with TNG Digital, Ant International’s EPOS360 AI-as-a-Service platform now supports more than 14,000 Malaysian SMEs Ant International today officially opened its Global Development Centre (GDC) in Kuala Lumpur, deepening its long-term commitment to Malaysia and Southeast Asia, and strengthening the country's role as a strategic hub for global innovation, digital talent, and next-generation financial technology. The unveiling ceremony was officiated by the Prime Minister of Malaysia, YAB Dato' Seri Anwar Ibrahim. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260
Haleon to Accelerate AI-powered Transformation With New Five-year Microsoft Collaboration1.7.2026 11:00:00 CEST | Press release
Haleon, a consumer health company solely focused on better everyday health, today announces a new five-year collaboration with Microsoft to scale digital, data and AI capabilities across the business and accelerate delivery of its global Win as One strategy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630342896/en/ The new agreement builds on Haleon’s existing use of Microsoft 365 Copilot and further supports the wider adoption of AI-powered tools across the business, helping teams automate routine tasks, collaborate more effectively and focus on higher-value work. Importantly, it will also further strengthen Haleon’s digital and AI-enabled infrastructure through further adoption of Microsoft’s agentic AI, security and identity capabilities, helping the company to scale AI securely and responsibly. Haleon and Microsoft will co-create high-impact AI use cases which deliver value across multiple critical functions, from
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom